Search

everythinglearnresearchcommunity

for

Search:↓

SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.

Finasteride effectively inhibits the enzyme steroid 5 alpha-reductase II.

Some prostate cancers have gene changes that may affect treatment with certain drugs.

Inhibiting testosterone 5alpha-reductase may help treat benign prostatic hyperplasia.

Human bone cells mainly produce a type 1 enzyme that may help regulate bone health.

GI197111X is best dissolved in Capmul MCM for trials.

Finasteride safely treats enlarged prostate and male-pattern baldness.

A new method was developed to measure and assess the activity and inhibition of the enzyme steroid 5α-reductase.

5α-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT levels.

Females with 5 alpha-reductase-2 deficiency have less body hair, no acne, normal fertility, and delayed menarche.

Some men's prostate tissues have low enzyme levels due to genetic changes, possibly affecting treatment for prostate enlargement.

Finasteride is made through a series of chemical reactions starting from a specific intermediate compound.

Androgens regulate 5 alpha-reductase activity in hamster sebaceous glands.

Methylation of the 5-AR2 gene may cause resistance to Finasteride in BPH patients.

2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.

The role of 5α-reductase-3 in prostate cancer is unclear and needs more research.

The P133R mutation in AKR1D1 enzyme causes harmful bile acid buildup, explaining related health issues.

The substance MK386 effectively blocked testosterone conversion and reduced cell growth in certain skin cells, but inhibiting 5α-reductase alone may not greatly improve acne.

5α-Reductase inhibitors can negatively impact sexual function.

Certain compounds, especially those with a propionic substituent, could potentially be new treatments for hair loss and similar disorders.

Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.

Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.

Mice lacking steroid 5α-reductase 2 show less aggression and better impulse control.

New compounds may soon be tested to treat excessive hair growth in women.

A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.

A new compound effectively inhibits human 5α-reductase 1.

Reducing 5α-reductase activity helps endometrial cells differentiate, aiding pregnancy.

Male pattern baldness is likely caused by multiple genes, not just 5α-reductase genes.